Retroauricular subperiosteal vs systemic intravenous glucocorticoid administration on efficacy and blood glucose in diabetic patients with sudden deafness

Table 4 Course of type 2 diabetes mellitus and therapeutic method are independent risk factors for therapeutic efficacy, n (%)

	Ineffective (n = 21)	Non-ineffective (n = 107)	Univariate analysis		Multivariate analysis
			OR	P value	OR	P value
Age, years old			0.565 (0.217-1.453)	0.234
≤ 60	10 (47.62)	66 (61.68)
> 60	11 (52.38)	41 (38.32)
Sex			0.974 (0.358-2.943)	0.960
Male	15 (71.43)	77 (71.96)
Female	6 (28.57)	30 (28.04)
BMI, kg/m²			0.530 (0.178-1.415)	0.224
≤ 24	6 (28.57)	46 (42.99)
> 24	15 (71.43)	61 (57.01)
Affected ear			1.121 (0.437-2.903)	0.811
Left	11 (52.38)	53 (49.53)
Right	10 (47.62)	54 (50.47)
History of smoking			1.701 (0.439-5.499)	0.399
With	4 (19.05)	13 (12.15)
Without	17 (80.95)	94 (87.85)
Dizziness			1.319 (0.280-4.675)	0.690
With	3 (14.29)	12 (11.21)
Without	18 (85.71)	95 (88.79)
Hypertension			1.952 (0.746-5.072)	0.167
With	10 (47.62)	34 (31.78)
Without	11 (52.38)	73 (68.22)
Hyperlipidemia			0.974 (0.296-2.766)	0.962
With	5 (23.81)	26 (24.30)
Without	16 (76.19)	81 (75.70)
Course of T2DM, years			0.197 (0.044-0.626)	0.013	0.171 (0.038-0.557)	0.008
≤ 5	3 (14.29)	49 (45.79)
> 5	18 (85.71)	58 (54.21)
Residence			0.647 (0.220-2.177)	0.448
Urban	16 (76.19)	89 (83.18)
Rural	5 (23.81)	18 (16.82)
Therapeutic method			0.313 (0.105-0.835)	0.026	0.267 (0.086-0.738)	0.014
Retroauricular subperiosteal injection of glucocorticoids injection	6 (28.57)	60 (56.07)
Systemic intravenous administration of glucocorticoids	15 (71.43)	47 (43.93)

BMI: Body mass index; OR: Odds ratio; T2DM: Type 2 diabetes mellitus.